Description: Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Home Page: www.rezolutebio.com
RZLT Technical Analysis
201 Redwood Shores Parkway
Redwood City,
CA
94065
United States
Phone:
650 206 4507
Officers
| Name | Title |
|---|---|
| Mr. Nevan Charles Elam J.D. | Founder, CEO & Director |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Mr. Chris Milks | VP & Head of Fin. |
| Mr. Michael R. Deperro | Sr. VP & Head of Technical Operations |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs |
| Mr. Michael Covarrubias | VP & Head of CMC |
| Dr. Raj Agrawal M.D. | VP & Head of Ophthalmological Clinical Devel. |
| Ms. Robyn Sweinhart | VP & Head of Quality |
| Ms. Erin O'Boyle | VP & Head of Clinical Operations |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9115 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-05-01 |
| Fiscal Year End: | June |
| Full Time Employees: | 42 |